EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Lack of alpha CGRP exacerbates the development of atherosclerosis in ApoE-knockout mice

Narumi Hashikawa-Hobara, Shota Inoue, Naoya Hashikawa

Scientific Reports · 2024

DOI: 10.1038/s41598-024-69331-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Narumi Hashikawa-Hobara und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Okayama University of Science, 1-1 Ridai-Cho, Kita-Ku, Okayama, 700-0005, Japan. hashikawa-hobara@ous.ac.jp. Hauptthemen laut MEDLINE: Atherosclerosis, Calcitonin Gene-Related Peptide, Apolipoproteins E, Plaque, Atherosclerotic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effects of calcitonin gene-related peptide (CGRP) on atherosclerosis remain unclear. We used apolipoprotein E-deficient (ApoE-/-) mice to generate double-knockout ApoE-/-:CGRP-/- mice lacking alpha CGRP. ApoE-/-:CGRP-/- mice exhibited larger atherosclerotic plaque areas, peritoneal macrophages with enhanced migration functions, and elevated levels of the inflammatory cytokine tumor necrosis factor (TNF)-⍺. Thus, we also explored whether inhibiting TNF-⍺ could improve atherosclerosis in ApoE-/-:CGRP-/- mice by administering etanercept intraperitoneally once a week (5 mg/kg) alongside a high-fat diet for 2 weeks. This treatment led to significant reductions in aortic root lesion size, atherosclerotic plaque area and macrophage migration in ApoE-/-:CGRP-/- mice compared with mice treated with human IgG (5 mg/kg). We further examined whether results observed in ApoE-/-:CGRP-/- mice could similarly be obtained by administering a humanized monoclonal CGRP antibody, galcanezumab, to ApoE-/- mice. ApoE-/- mice were subcutaneously administered galcanezumab at an initial dose of 50 mg/kg, followed by a dose of 30 mg/kg in the second week. Galcanezumab administration did not affect systolic blood pressure, serum lipid levels, or macrophage migration but led to a significant increase in lipid deposition at the aortic root. These findings suggest that alpha CGRP plays a critical role in inhibiting the progression of atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisCalcitonin Gene-Related PeptideApolipoproteins EPlaque, AtheroscleroticMice, KnockoutAnimalsMiceDiet, High-FatTumor Necrosis Factor-alphaMaleMice, Knockout, ApoEDisease Models, AnimalHumansAntibodies, Monoclonal, HumanizedEtanerceptMice, Inbred C57BLCell MovementAorta

Substanzen

Calcitonin Gene-Related PeptideApolipoproteins ETumor Necrosis Factor-alphaAntibodies, Monoclonal, HumanizedEtanercept

Autor:innen und Institutionen

  • Department of Life Science, Okayama University of Science, 1-1 Ridai-Cho, Kita-Ku, Okayama, 700-0005, Japan. hashikawa-hobara@ous.ac.jp.
  • Department of Life Science, Okayama University of Science, 1-1 Ridai-Cho, Kita-Ku, Okayama, 700-0005, Japan.

Zitieren

APA

Hashikawa-Hobara, N., Inoue, S., & Hashikawa, N. (2024). Lack of alpha CGRP exacerbates the development of atherosclerosis in ApoE-knockout mice. Scientific Reports. https://doi.org/10.1038/s41598-024-69331-5

Vancouver

Hashikawa-Hobara N, Inoue S, Hashikawa N. Lack of alpha CGRP exacerbates the development of atherosclerosis in ApoE-knockout mice. Scientific Reports. 2024. doi:10.1038/s41598-024-69331-5

BibTeX
@article{HashikawaHobara2024,
  author = {Hashikawa-Hobara, Narumi and Inoue, Shota and Hashikawa, Naoya},
  title = {Lack of alpha CGRP exacerbates the development of atherosclerosis in ApoE-knockout mice},
  journal = {Scientific Reports},
  year = {2024},
  doi = {10.1038/s41598-024-69331-5}
}
Kostenlos starten →